Status:
COMPLETED
OLGA and OLGIM Stage System for Gastric Cancer
Lead Sponsor:
Seoul National University Bundang Hospital
Collaborating Sponsors:
National Clinical Research Coordination Center, Seoul, Korea
Conditions:
Stomach Neoplasms
Atrophic Gastritis
Eligibility:
All Genders
25-80 years
Brief Summary
To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interactio...
Detailed Description
To validated the OLGA and OLGIM staging system with serum pepsinogen to estimate gastric cancer risk according to Lauren's histologic classification in South Korea, where the incidence rate of GC is h...
Eligibility Criteria
Inclusion
- Control group
- those who were between 25 and 80 years old and did not have any evidence of gastric cancer and gastric dysplasia, esophageal tumor and MALToma in upper gastrointestinal endoscopy
- Gastric cancer group
- Patients diagnosed as gastric cancer in the upper gastrointestinal endoscopy at the time of participating in the study between 25 and 80 years old.
Exclusion
- history of previous gastrointestinal surgery,
- any other malignancy
- cardia cancer
- who do not perform endoscopic biopsy
- pathologically proven gastric dysplasia
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
2900 Patients enrolled
Trial Details
Trial ID
NCT03380052
Start Date
February 1 2006
End Date
January 1 2022
Last Update
April 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 463-707